Immorta Bio has completed preclinical work on SenoMune-0257, a nine-amino-acid synthetic peptide identified through AI screening that stimulates cytotoxic T cells to selectively clear senescent cells. The approach shifts from directly killing these cells with small molecules to restoring immune surveillance, with the aim of durable immunological memory and lower off-target toxicity. Human evaluation is anticipated before year-end, though trial design, site and regulatory status remain undisclosed.
Key Points
- AI-identified nine-amino-acid peptide directs T cells against senescent cells
- Immune-mediated clearance targets senolytic off-target toxicity and memory limitations
- Preclinical data only; trial location, size and regulatory status undisclosed
Longevity Analysis
Senescent cell accumulation links chronic low-grade inflammation to deterioration across vascular, hepatic, renal, pulmonary and neural tissue, which is why clearance strategies have drawn sustained attention. Restoring immune recognition rather than applying a cytotoxic agent addresses the central problem with first-generation senolytics: interference is removed by the body's own defenses, which can retain memory of the target, rather than by repeated pharmacological exposure that risks damaging healthy tissue. The evidence base remains preclinical and company-reported, so the relevant question for clinicians is whether selective killing holds in humans and whether functional regeneration follows clearance.
Original published by Longevity.Technology, by Kyle Umipig.